Medtronic Increases Fiscal 2027 Forecasts Amid Heart Device Demand Surge

Medtronic has revised its fiscal 2027 financial projections upward, anticipating robust demand for its heart devices used in complex cardiovascular procedures. The medical technology company announced the adjustment on Tuesday, highlighting the significant contribution from its innovative product lines.

Strong Financial Outlook

The company has increased the lower end of its adjusted per share profit forecast for fiscal 2027 to $5.94 from $5.90, while maintaining the upper end at $6. Additionally, Medtronic now expects annual organic revenue growth to range between 7.25% and 7.75%, a rise from the previous estimate of 6.75% to 7.25%. CEO Geoff Martha expressed confidence in the company's performance, citing a broad-based strength across its business units and growing contributions from new growth platforms.

Strategic Investments and Acquisitions

In a strategic move, Medtronic has announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire it for $210 million. Furthermore, the company has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the U.S. Martha noted the potential growth in soft tissue robotic surgery, especially in emerging markets where penetration remains below 1%.

Medtronic's focus on mergers and acquisitions underscores its strategy to prioritize high-growth segments within the medtech industry. Martha emphasized the importance of targeting large patient pools and significant market segments.

Cardiovascular Segment Performance

The company reported a remarkable 19.5% increase in sales within its cardiovascular segment, reaching $3.93 billion. This growth was largely driven by its pulsed field ablation portfolio, which experienced an 88% surge as it addresses irregular heart rhythms. For the quarter, Medtronic posted an adjusted per share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Despite receiving tariff refunds that nearly offset the duties paid during the quarter, Medtronic's finance chief Thierry Pieton stated that future refunds have not been factored into the company's outlook.